| Overview |
| bsm-41203M-Cy7 |
| phospho-Alpha synuclein(Ser129) Monoclonal Antibody, Cy7 Conjugated |
| WB, FCM, IF(ICC) |
| Human, Mouse, Rat |
| Specifications |
| Cy7 |
| Mouse |
| KLH conjugated Synthesised phosphopeptide derived from human alpha-synuclein around the phosphorylation site of Ser129 |
| Monoclonal |
| 6B7 |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 6622 |
| P37840 |
| Cytoplasm, Nucleus, Cytomembrane |
| Alpha-synuclein (phospho S129); Alpha-synuclein (p-S129); Alpha synuclein; Alpha-Synuclein; Alpha-synuclein, isoform NACP140; alpha SYN; MGC105443; MGC110988; MGC127560; MGC64356; NACP; Non A beta component of AD amyloid; Non A4 component of amyloid precursor; Non-A-beta component of alzheimers disease amyloid , precursor of; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; PARK 1; PARK 4; PARK1; PARK4; Parkinson disease (autosomal dominant, Lewy body) 4; Parkinson disease familial 1; PD 1; PD1; Syn; SNCA; Snca synuclein, alpha (non A4 component of amyloid precursor); SYUA_HUMAN; Synuclein alpha; Synuclein, alpha (non A4 component of amyloid precursor); |
| May be involved in the regulation of dopamine release and transport. Induces fibrillization of microtubule-associated protein tau. Reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase-3 activation. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(ICC) |
1:50-200 |
Powered by Bioz